Kevin Dunleavy

1 week ago | fiercepharma.com | Ayla Ellison |Eric Sagonowsky |Kevin Dunleavy |Gabrielle Masson

Despite the long holiday weekend, news in biopharma never slows down. In this week’s episode of "The Top Line," the Fierce team breaks down some of the biggest stories from the past week. On the pharma side, Eric Sagonowsky and Kevin Dunleavy examine Big Pharma’s first-quarter 2025 performance. While most of the top 25 companies are still delivering strong sales growth despite emerging uncertainties in Washington, D.C., a few major players are starting to see a slowdown.

1 week ago | fiercepharma.com | Kevin Dunleavy

Six years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first FDA approval for a prescription drug, scoring a nod for dry eye disease (DED) treatment Tryptyr (acoltremon ophthalmic solution). Tryptyr, which is administered as a single drop twice daily, is a first-in-class TRPM8 receptor agonist intended to activate tear production.

1 week ago | fiercepharma.com | Kevin Dunleavy

A month after the FDA lifted its clinical hold on GSK’s vaginal yeast infection drug Brexafemme (ibrexafungerp), the developer of the treatment, Scynexis, has resumed a phase 3 study in another use. The dosing of the first new patient in the MARIO study triggers a $10 million milestone payment from GSK and another $20 million due in six months, the Jersey City-based biotech said in a May 28 press release. GSK, for its part, is disputing the charges, according to Scynexis.

1 week ago | fiercepharma.com | Kevin Dunleavy

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers in the first three months of 2025. The companies that took the biggest hits were in the United States, where there is already considerable angst in the industry over the tariff threats and drug price-slashing aspirations of President Donald Trump, along with the unsettling prospects of having a pharma adversary, Robert F.

2 weeks ago | fiercepharma.com | Kevin Dunleavy

Who doesn’t love a comeback story? Certainly not GSK, which has found a way to resuscitate its cancer treatment Blenrep as a combo agent after it was pulled from the U.S. market as a monotherapy in late 2022. This week, Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended Blenrep for approval for patients with relapsed or refractory multiple myeloma.